A Phase II Study of CCX282-B in Patients With Celiac Disease

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ChemoCentryx

Criteria

Key Inclusion Criteria:

• Male or female, between 18 and 75 years of age

• Established diagnosis of celiac disease

• Subject has been following a strict gluten-free diet for at least 24 months

Key Exclusion Criteria:

• History of any infection requiring intravenous antibiotics, a serious local infection, systemic infection, or gastrointestinal infection within 12 weeks of randomization

• Use of any immunosuppressants, TNF inhibitors, or natalizumab during the 12 weeks prior to study randomization

• Use of steroids during the 4 weeks prior to study randomization

• Receipt of an experimental treatment for any disease within 4 weeks prior to randomization

• Known IgE-mediated atopy or allergy or anaphylactic reactions to gluten

• The subject suffers from a condition that carries a risk at endoscopy or is on anticoagulant treatment